This is a continuance of the licensing partnership arGentis has with the Southern College of Optometry and becomes the third prospective therapy for dry eye syndrome (DES) that utilizes the transdermal delivery of an active pharmaceutical ingredient to affected glands via application of a cream or gel to the outer, upper and lower eyelids.
ARG103 incorporates a combination of the hormones testosterone and progesterone. By combining progesterone with testosterone in ARG103, a larger number of post-menopausal women may respond to treatment. ARG103 is said to broaden the reach of arGentis’s transdermal ocular technology, which includes ARG101 for use in menopausal women and ARG102, a progesterone-based formulation that treats DES in younger women and men.
Tom Davis, CEO of arGentis Pharmaceuticals, said: “ARG103 strengthens our business and allows arGentis to offer effective treatment options using the novel transdermal delivery method to a larger patient population.”